NASDAQ:LPCN

Lipocine (LPCN) Stock Forecast, Price & News

$2.83

-0.15 (-5.03%)

(As of 10/2/2023 ET)

Compare

Today's Range: $2.76
▼
$3.06
50-Day Range: $2.83
▼
$5.10
52-Week Range: $2.76
▼
$10.33

Volume: 14,597 shs
Average Volume: 69,043 shs
Market Capitalization: $15.04 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $68.00

Lipocine MarketRank™ Forecast

Analyst Rating: 0.00 Rating Score
Upside/Downside: 2,302.8% Upside
$68.00 Price Target
Short Interest: Healthy
2.53% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.30
Based on 3 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($2.70) to ($1.91) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.60 out of 5 stars

Medical Sector

875th out of 969 stocks

Pharmaceutical Preparations Industry

413th out of 452 stocks

2.0

Analyst's Opinion

Price Target Upside/Downside
According to analysts' consensus price target of $68.00, Lipocine has a forecasted upside of 2,302.8% from its current price of $2.83.
Amount of Analyst Coverage
Lipocine has received no research coverage in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
2.53% of the float of Lipocine has been sold short.
Short Interest Ratio / Days to Cover
Lipocine has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Lipocine has recently increased by 52.04%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Lipocine does not currently pay a dividend.
Dividend Growth
Lipocine does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for LPCN.

2.9

News and Social Media Coverage

News Sentiment
Lipocine has a news sentiment score of 0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.70 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Lipocine this week, compared to 0 articles on an average week.
Search Interest
6 people have searched for LPCN on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
MarketBeat Follows
3 people have added Lipocine to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Lipocine insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 5.00% of the stock of Lipocine is held by insiders.
Percentage Held by Institutions
Only 8.99% of the stock of Lipocine is held by institutions.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Lipocine are expected to grow in the coming year, from ($2.70) to ($1.91) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Lipocine is -1.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Lipocine is -1.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Lipocine has a P/B Ratio of 0.41. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Lipocine (NASDAQ:LPCN) Stock

Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company's pipeline candidates also include LPCN 1154 for postpartum depression; LPCN 2101 for women with epilepsy; and LPCN 1148, a novel prodrug of testosterone, testosterone laurate for the management of decompensated cirrhosis. It also develops LPCN 1144, an oral prodrug of androgen receptor modulator for the treatment of non-cirrhotic non-alcoholic steatohepatitis, which has completed Phase II testing; LPCN 1111, an oral TRT product of testosterone tridecanoate for once daily dosing, which has completed Phase II clinical testing; and LPCN 1107, an oral hydroxy progesterone caproate product for the prevention of recurrent preterm birth. Lipocine Inc. was founded in 1997 and is headquartered in Salt Lake City, Utah.

LPCN Price History

30 days | 90 days | 365 days | Advanced Chart

LPCN Stock News Headlines

September 28, 2023 | americanbankingnews.com

StockNews.com Initiates Coverage on Lipocine (NASDAQ:LPCN)

September 19, 2023 | finance.yahoo.com

Lipocine to Present at the Cantor Fitzgerald Global Healthcare Conference

October 2, 2023 | Legacy Research (Ad)

Elon Did It Again: This Could be Bigger than Tesla

Love him or hate him, it’s hard to deny Elon Musk is a genius. After revolutionizing online payment processing (PayPal), space exploration (SpaceX), and the auto industry (Tesla)... He’s getting ready to do it again with his new AI venture.

August 17, 2023 | stocknews.com

Looking for a Value Investment? Check out These 3 Pharma Stocks

August 16, 2023 | finance.yahoo.com

LPCN: Trial Results Improve Outlook

August 10, 2023 | finance.yahoo.com

Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2023

July 31, 2023 | finance.yahoo.com

LPCN: 1148 Shows Muscle Loss Reversal

July 27, 2023 | benzinga.com

Why Lipocine Stock Is Moving Higher Today?

October 2, 2023 | Legacy Research (Ad)

Elon Did It Again: This Could be Bigger than Tesla

July 27, 2023 | investorplace.com

Why Is Lipocine (LPCN) Stock Up 32% Today?

June 14, 2023 | finance.yahoo.com

Lipocine to Present at H.C. Wainwright Annual Neuropsychiatry Virtual Conference

June 7, 2023 | finance.yahoo.com

Lipocine to Present LPCN 1148 and LPCN 1144 at the EASL Congress 2023

May 16, 2023 | msn.com

Lipocine stock dips after bridging study data of LPCN 1154 for postpartum depression

May 16, 2023 | finance.yahoo.com

Positive Topline Clinical Results Support Streamlined Development Pathway for LPCN 1154, Lipocine's Oral Candidate for Rapid Relief of Depression

May 12, 2023 | msn.com

Recap: Lipocine Q1 Earnings

May 11, 2023 | apnews.com

Lipocine: Q1 Earnings Snapshot

May 11, 2023 | finance.yahoo.com

Lipocine Announces Financial Results for the First Quarter Ended March 31, 2023

April 3, 2023 | finance.yahoo.com

First Subject Dosed in the Clinical Bridge Study with Lipocine Depression Candidate, LPCN 1154

March 16, 2023 | finance.yahoo.com

LPCN: 2022 Operational & Financial Update

March 10, 2023 | finance.yahoo.com

Lipocine Announces Pro Rata Distribution of Series B Preferred Stock to its Holders of Common Stock

March 10, 2023 | finance.yahoo.com

Lipocine Announces Financial Results for the Year Ended December 31, 2022

January 16, 2023 | finance.yahoo.com

Is Lipocine Inc.'s (NASDAQ:LPCN) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?

January 5, 2023 | finance.yahoo.com

Lipocine to Present at Biotech Showcase

December 19, 2022 | finance.yahoo.com

Lipocine Completes Enrollment of LPCN 1148 Phase 2 Study for Decompensated Cirrhosis

November 9, 2022 | finance.yahoo.com

Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2022

November 3, 2022 | finance.yahoo.com

Lipocine Announces Senior Leadership Appointments to Advance its CNS-Focused Pipeline

October 11, 2022 | finance.yahoo.com

Lipocine to Present at H.C. Wainwright 6th Annual NASH Investor Conference - Yahoo Finance

See More Headlines

Receive LPCN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lipocine and its competitors with MarketBeat's FREE daily newsletter.

LPCN Company Calendar

Last Earnings: 8/10/2023
Today: 10/02/2023
Next Earnings (Estimated): 11/08/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:LPCN
CUSIP: N/A
CIK: 1535955
Web: www.lipocine.com
Phone: (801) 994-7383
Fax: 801-994-7388
Employees: 15
Year Founded: 1997

Price Target and Rating

Average Stock Price Forecast: $68.00
High Stock Price Forecast: $68.00
Low Stock Price Forecast: $68.00
Forecasted Upside/Downside: +2,277.6%
Consensus Rating
Rating Score (0-4): 0.00
Research Coverage: 0 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.3807)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-10,760,000.00
Net Margins: N/A
Pretax Margin: -21,921.82%
Return on Equity: -36.05%
Return on Assets: -34.09%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 14.82
Quick Ratio: 14.82

Sales & Book Value

Annual Sales: $500,000.00
Price / Sales: 30.43
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $6.85 per share
Price / Book: 0.42

Miscellaneous

Outstanding Shares: 5,320,000
Free Float: 5,040,000
Market Cap: $15.22 million
Optionable: Optionable
Beta: 1.04

Social Links

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

Dr. Mahesh V. Patel Ph.D. (Age 66)
Co-Founder, Interim Principal Financial Officer, Director, Pres & CEO
Comp: $598.91k

Ms. Krista Fogarty (Age 55)
Principal Accounting Officer & Corp. Controller
Comp: $268.12k

Dr. Nachiappan Chidambaram Ph.D. (Age 53)
Sr. VP of R&D
Comp: $311.17k

Mr. Logan Morse (Age 53)
VP of Sales, Marketing & Operations

Mr. Morgan R. Brown CPA (Age 55)
CPA, M.B.A., MBA, Corp. Sec.

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

LPCN Stock - Frequently Asked Questions

What is Lipocine's stock price forecast for 2023?: 0 Wall Street research analysts have issued 1 year price targets for Lipocine's stock. Their LPCN share price forecasts range from $68.00 to $68.00. On average, they predict the company's share price to reach $68.00 in the next twelve months. This suggests a possible upside of 2,277.6% from the stock's current price.
View analysts price targets for LPCN or view top-rated stocks among Wall Street analysts.
How have LPCN shares performed in 2023?: Lipocine's stock was trading at $6.7626 at the beginning of 2023. Since then, LPCN shares have decreased by 57.7% and is now trading at $2.86.
View the best growth stocks for 2023 here.
Are investors shorting Lipocine?: Lipocine saw a increase in short interest during the month of September. As of September 15th, there was short interest totaling 130,600 shares, an increase of 52.0% from the August 31st total of 85,900 shares. Based on an average daily volume of 163,900 shares, the days-to-cover ratio is currently 0.8 days. Currently, 2.5% of the shares of the company are short sold.
View Lipocine's Short Interest.
When is Lipocine's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023.
View our LPCN earnings forecast.
How were Lipocine's earnings last quarter?: Lipocine Inc. (NASDAQ:LPCN) announced its quarterly earnings data on Thursday, August, 10th. The specialty pharmaceutical company reported ($0.68) earnings per share for the quarter, missing the consensus estimate of ($0.64) by $0.04.
When did Lipocine's stock split?: Lipocine's stock reverse split before market open on Friday, May 12th 2023. The 1-17 reverse split was announced on Friday, May 12th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, May 12th 2023. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split.

What other stocks do shareholders of Lipocine own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Lipocine investors own include Synergy Pharmaceuticals (SGYP), Flexion Therapeutics (FLXN), Trevena (TRVN), Heat Biologics (HTBX), Rigel Pharmaceuticals (RIGL), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Dynavax Technologies (DVAX), Biocept (BIOC) and Catalyst Pharmaceuticals (CPRX).
What is Lipocine's stock symbol?: Lipocine trades on the NASDAQ under the ticker symbol "LPCN."
How do I buy shares of Lipocine?: Shares of LPCN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Lipocine's stock price today?: One share of LPCN stock can currently be purchased for approximately $2.86.
How much money does Lipocine make?: Lipocine (NASDAQ:LPCN) has a market capitalization of $15.22 million and generates $500,000.00 in revenue each year. The specialty pharmaceutical company earns $-10,760,000.00 in net income (profit) each year or ($2.3807) on an earnings per share basis.
How can I contact Lipocine?: Lipocine's mailing address is 675 ARAPEEN DRIVE SUITE 202, SALT LAKE CITY X1, 84108. The official website for the company is www.lipocine.com. The specialty pharmaceutical company can be reached via phone at (801) 994-7383, via email at john.woolford@westwicke.co, or via fax at 801-994-7388.

This page (NASDAQ:LPCN) was last updated on 10/2/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial